Eculizumab biosimilar - Amgen

Drug Profile

Eculizumab biosimilar - Amgen

Alternative Names: ABP 959

Latest Information Update: 04 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Antiallergics; Antianaemics; Antiasthmatics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Neuroprotectants; Skin disorder therapies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Paroxysmal nocturnal haemoglobinuria
  • Phase I Haemolytic uraemic syndrome

Most Recent Events

  • 04 Sep 2017 Phase-III clinical trials in Paroxysmal nocturnal haemoglobinuria in Spain (IV) before September 2017(EudraCT2017-001418-27)
  • 25 Mar 2017 Amgen completes a phase I trial in Paroxysmal nocturnal haemoglobinuria and Haemolytic uraemic syndrome (In volunteers) in Australia (IV) (ACTRN12616000509460)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top